Information Provided By: 
Fly News Breaks for February 8, 2018
HUM
Feb 8, 2018 | 05:21 EDT
Credit Suisse analyst A.J. Rice upgraded Humana to Outperform and raised his price target for the shares to $306 from $259. After ceding market share for "several years," Humana should return to above market individual Medicare Advantage enrollment growth in 2019 as it benefits from a favorable rate update and tax reform, Rice tells investors in a research note. He sees "several drivers" that support his core operating earnings growth assumption of 12% in 2018.
News For HUM From the Last 2 Days
HUM
Apr 16, 2024 | 09:56 EDT
Notable gainers among liquid option names this morning include UnitedHealth (UNH) $475.73 +30.10, Super Micro (SMCI) $914.90 +32.15, Humana (HUM) $324.54 +9.90, Morgan Stanley (MS) $89.42 +2.43, and Cencora Inc (COR) $238.39 +4.18.
HUM
Apr 15, 2024 | 10:37 EDT
Shares of health care facilities and managed care are in the spotlight on Monday after Florida announced late on Friday five winners of six-year Medicaid managed care contracts. Among the winners... To see the rest of the story go to thefly.com. See Story Here
HUM
Apr 15, 2024 | 06:16 EDT
HUM
Apr 15, 2024 | 06:15 EDT
Wells Fargo raised the firm's price target on Centene (CNC) to $93 from $89 and keeps an Overweight rating on the shares. The firm notes Florida intends to award Medicaid contracts to Centene, Elevance Health (ELV), Humana (HUM) and two provider-run plans. Clearly the most positive for Centene given recent disappointing RFP performance and likely most disappointing for Molina Healthcare (MOH) given expectation for share gains, Wells says.
